Interspecies scaling and prediction of human clearance: Comparison of small- and macro-molecule drugs

Xenobiotica

Volumn 41, Issue 11, 2011, Pages 972-987

  Huh, Yeamin ^a   Smith, David E ^a   Rose Feng, Meihau ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Human clearance prediction; Interspecies scaling; Liver blood flow; Macro molecule; Small molecule

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEFACEPT; ALTEPLASE; APRINOCARSEN; BASILIXIMAB; CETRORELIX; CGP 69846A; CNTO 136; CYCLOSPORIN; DALBAVANCIN; DAPTOMYCIN; DESMOPRESSIN; DIGOXIN; DROTRECOGIN; DRUG; FONDAPARINUX; GAVESTINEL; GLASPIMOD; GLUCAGON; INTETUMUMAB; ISIS 104838; ISIS 2503; LEUPRORELIN; MIPOMERSEN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OCTREOTIDE; PAMITEPLASE; PNU 288034; PNU 96391; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RELAXIN; RETEPLASE; RO 246173; RO 256833; RSHZ 19; SILTUXIMAB; SINITRODIL; TEICOPLANIN; TELAVANCIN; TENECTEPLASE; TRICHOSANTHIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VANCOMYCIN;

ALLOMETRY; ARTICLE; BRAIN WEIGHT; DRUG CLEARANCE; HUMAN; LIVER BLOOD FLOW; LIVER CLEARANCE; MACROMOLECULE; MOLECULAR WEIGHT; NONHUMAN; PREDICTION; SPECIES DIFFERENCE;

ANIMALS; HUMANS; LIVER; MACROMOLECULAR SUBSTANCES; MOLECULAR WEIGHT; PHARMACEUTICAL PREPARATIONS; REGIONAL BLOOD FLOW; SMALL MOLECULE LIBRARIES; SPECIES SPECIFICITY;

EID: 80053940972     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.598582     Document Type: Article

References (154)

1. Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J. (2002). Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects. Clin Pharmacol Ther 71:186-195. (Pubitemid 34271122)
2. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX. (2006). Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55:717-727.
3. Agerso H, Seiding Larsen L, Riis a, Lovgren U, Karlsson M O, Senderovitz T. (2004). Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol 58:352-358. (Pubitemid 39312458)
4. Aggarwal S. (2007). What's fueling the biotech engine? Nat Biotechnol 25:1097-1104.
5. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. (2005). Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:2534-2543. (Pubitemid 47050843)
6. Bachmann K. (1989). Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species. J Appl Toxicol 9:331-338. (Pubitemid 19230512)
7. Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR. (1999). Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27:397-420. (Pubitemid 30228022)
8. Bazin-Redureau M, Pepin S, Hong G, Debray M, Scherrmann JM. (1998). Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. Toxicol Appl Pharmacol 150:295-300. (Pubitemid 28302513)
9. Belpaire FM, de Smet F, Vynckier LJ, Vermeulen AM, Rosseel MT, Bogaert MG, Chauvelot-Moachon L. (1990). Effect of aging on the pharmcokinetics of atenolol, metoprolol and propranolol in the rat. J Pharmacol Exp Ther 254:116-122. (Pubitemid 20262029)
10. Bjorkman S, Redke F. (2000). Clearance of fentanyl, alfentanil, methohexitone, thiopentone and ketamine in relation to estimated hepatic blood flow in several animal species: application to prediction of clearance in man. J Pharm Pharmacol 52:1065-1074.
11. Bleuel H, Hoffmann R, Kaufmann B, Neubert P, Ochlich PP, Schaumann W. (1996). Kinetics of subcutaneous versus intravenous epoetinbeta in dogs, rats and mice. Pharmacology 52:329-338. (Pubitemid 26162792)
12. Bolton, S. (1997) Pharmaceutical statistics: practical and clinical applications, New York, Marcel Dekker Inc.
13. Bortolotti A, Castelli D, Verotta D, Bonati M. (1989). Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. Eur J Drug Metab Pharmacokinet 14:145-151. (Pubitemid 19249426)
14. Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201-227. (Pubitemid 12044187)
15. Boxenbaum H, DiLea C. (1995). First-time-in-human dose selection: allometric thoughts and perspectives. J Clin Pharmacol 35:957-966.
16. Braeckman, R. (2000) Pharmacokinetics and pharmacodynamics of protein therapeutics, CRC Press.
17. Brocks DR, Freed MI, Martin DE, Sellers TS, Mehdi N, Citerone DR, Boppana V, Levitt B, Davies BE, Nemunaitis J, Jorkasky DK. (1996). Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients. Pharm Res 13:794-797.
18. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407-484. (Pubitemid 27314117)
19. Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C. (2007). Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 62:43-52. (Pubitemid 46330791)
20. Cernacek P, Maher E, Crawhall JC, Levy M. (1988). Renal dose response and pharmacokinetics of atrial natriuretic factor in dogs. Am J Physiol 255:R929-R935.
21. Chang T, Black A, Dunky A, Wolf R, Sedman A, Latts J, Welling PG. (1988). Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. J Antimicrob Chemother 21 Suppl B:49-56.
22. Cohenuram M, Saif MW. (2007). Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18:7-15. (Pubitemid 44949790)
23. Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM. (1991). Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. Circulation 84:1216-1234.
24. Crombet T, Torres O, Neninger E, Catala M, Rodriguez N, Ramos M, Fernandez E, Iznaga N, Perez R, Lage A. (2001). Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. Cancer Biother Radiopharm 16:93-102. (Pubitemid 32231721)
25. Cruze CA, Kelm GR, Meredith MP. (1995). Interspecies scaling of tebufelone pharmacokinetic data and application to preclinical toxicology. Pharm Res 12:895-901.
26. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
27. Davis CB, Hepburn TW, Urbanski JJ, Kwok DC, Hart TK, Herzyk DJ, Demuth SG, Leland M, Rhodes GR. (1995). Preclinical pharmacokinetic evaluation of the respiratory syncytial virusspecific reshaped human monoclonal antibody RSHZ19. Drug Metab Dispos 23:1028-1036.
28. Davis LE, Westfall BA. (1972). Species differences in biotransformation and excretion of salicylate. Am J Vet Res 33:1253-1262.
29. Dedrick R, Bischoff KB, Zaharko DS. (1970). Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 54:95-101.
30. Dedrick RL, Forrester DD, Cannon JN, el-Dareer SM, Mellett LB. (1973). Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine (ARA-C) deamination in several species. Biochem Pharmacol 22:2405-2417.
31. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS. (2001). Pharmacokinetics of gemtuzumab ozogamicin, an antibodytargeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 41:1206-1214. (Pubitemid 32983219)
32. Doyle E, Chasseaud LF, Miller JN. (1982). Comparative pharmacokinetics of frusemide in female rhesus monkeys, cynomolgus monkeys and baboons. Comp Biochem Physiol C, Comp Pharmacol 71C:89-93. (Pubitemid 12188860)
33. Egrie JC FAU - Dwyer E, Dwyer E FAU - Browne, JK, Browne JK FAU - Hitz A, Hitz A FAU - Lykos, MA, Lykos, MA. (2003). Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.
34. Eriksson UG, Renberg L, Bredberg U, Teger-Nilsson AC, Regardh CG. (1998). Animal pharmacokinetics of inogatran, a low-molecularweight thrombin inhibitor with potential use as an antithrombotic drug. Biopharm Drug Dispos 19:55-64. (Pubitemid 28064491)
35. Evans CA, Jolivette LJ, Nagilla R, Ward KW. (2006). Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. Drug Metab Dispos 34:1255-1265.
36. Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, Herzyk DJ, Jorkasky DK. (1996). The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J Infect Dis 174:463-469. (Pubitemid 26299677)
37. Feldman HA, McMahon TA. (1983). The . mass exponent for energy metabolism is not a statistical artifact. Respir Physiol 52:149-163. (Pubitemid 13055195)
38. Feng MR, Loo J, Wright J. (1998). Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling. Drug Metab Dispos 26:982-988. (Pubitemid 28478259)
39. Feng MR, Lou X, Brown RR, Hutchaleelaha A. (2000). Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics. Pharm Res 17:410-418. (Pubitemid 30395295)
40. Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, Vlasses PH. (1990). Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 47:557-564. (Pubitemid 20190094)
41. Gatti G, Kahn JO, Lifson J, Williams R, Turin L, Volberding PA, Gambertoglio JG. (1991). Pharmacokinetics of GLQ223 in rats, monkeys, and patients with AIDS or AIDS-related complex. Antimicrob Agents Chemother 35:2531-2537.
42. Geary RS, Yu RZ, Levin AA. (2001). Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs 2:562-573. (Pubitemid 32401151)
43. Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA. (2003). Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2- methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 31:1419-1428. (Pubitemid 37310332)
44. Giachetti C, Bertolino M, Canali S, Lombardini E, Monzani MV, Sala A, Zanolo G. (1998). Pharmacokinetic study in dogs and monkeys after single intravenous and oral administrations of [14C]-ITF-296. Eur J Drug Metab Pharmacokinet 23:239-250. (Pubitemid 28401114)
45. Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, Hansen HJ, Chang CH. (2009). Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 113:1062-1070.
46. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. (2001). Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850. (Pubitemid 32119100)
47. Goteti K, Brassil PJ, Good SS, Garner CE. (2008). Estimation of human drug clearance using multiexponential techniques. J Clin Pharmacol 48:1226-1236.
48. Grene-Lerouge NA, Bazin-Redureau MI, Debray M, Scherrmann JM. (1996). Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. Toxicol Appl Pharmacol 138:84-89. (Pubitemid 26159598)
49. Guentert TW, Huang JD, Oie S. (1982). Disposition of quinidine in the rabbit. J Pharm Sci 71:812-815. (Pubitemid 12020323)
50. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, Abraham PA. (1991). Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50:702-712.
51. Harris PA, Gross JF. (1975). Preliminary pharmacokinetic model for adriamycin (NSC-123127). Cancer Chemother Rep 59:819-825.
52. Harrison MP, Moss SR, Featherstone A, Fowkes AG, Sanders AM, Case DE. (1989). The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother 24 Suppl A:265-277. (Pubitemid 19248748)
53. Hauptmann J. (2002). Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. A review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol 57:751-758. (Pubitemid 34143330)
54. Herault JP, Donat F, Barzu T, Crepon B, Bernat A, Lormeau JC, Herbert JM. (1997). Pharmacokinetic study of three synthetic AT-binding pentasaccharides in various animal species-extrapolation to humans. Blood Coagul Fibrinolysis 8:161-167. (Pubitemid 27241508)
55. Higuchi S, Shiobara Y. (1980). Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. Xenobiotica 10:447-454. (Pubitemid 10049541)
56. Hinderling PH, Dilea C, Koziol T, Millington G. (1993). Comparative kinetics of sematilide in four species. Drug Metab Dispos 21:662-669. (Pubitemid 23221762)
57. Hirai J, Miyazaki H, Taneike T. (1992). The pharmacokinetics and pharmacodynamics of furosemide in the anaesthetized dog. J Vet Pharmacol Ther 15:231-239.
58. Ho M, Silamut K, White NJ, Karbwang J, Looareesuwan S, Phillips RE, Warrell DA. (1990). Pharmacokinetics of three commercial antivenoms in patients envenomed by the Malayan pit viper, Calloselasma rhodostoma, in Thailand. Am J Trop Med Hyg 42:260-266. (Pubitemid 20109050)
59. Hu T-M, Chiu S-J. (2009). Prediction of human drug clearance using a single-species, fixed-exponent allometric approach. Journal of Medical Sciences 29:331-339.
60. Hu TM, Hayton WL. (2001). Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS PharmSci 3:E29.
61. Hutchaleelaha A, Chow HH, Mayersohn M. (1997). Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. J Pharm Pharmacol 49:178-183. (Pubitemid 27096112)
62. Iavarone L, Hoke JF, Bottacini M, Barnaby R, Preston GC. (1999). First time in human for GV196771: interspecies scaling applied on dose selection. J Clin Pharmacol 39:560-566. (Pubitemid 30629035)
63. Ishizuka M, Nagai S, Sakamoto KQ, Fujita S. (2007). Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. Xenobiotica 37:503-513. (Pubitemid 46809117)
64. Iven H. (1977). The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. Naunyn Schmiedebergs Arch Pharmacol 298:43-50. (Pubitemid 8102025)
65. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, Sugiyama Y. (1996). Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277:1630-1641. (Pubitemid 27167181)
66. Kagan L, Abraham AK, Harrold JM, Mager DE. (2010). Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res 27:920-932.
67. Kaul S, Dandekar KA, Schilling BE, Barbhaiya RH. (1999). Toxicokinetics of 2',3'-didehydro-3'-deoxythymidine, stavudine (D4T). Drug Metab Dispos 27:1-12.
68. Keith JC Jr, Ferranti TJ, Misra B, Frederick T, Rup B, McCarthy K, Faulkner R, Bush L, Schaub RG. (1995). Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. Thromb Haemost 73:101-105.
69. Kenny JR, Grime K. (2006). Pharmacokinetic consequences of timedependent inhibition using the isolated perfused rat liver model. Xenobiotica 36:351-365. (Pubitemid 43879737)
70. Kim SH, Kim WB, Lee MG. (1998). Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm Drug Dispos 19:231-235. (Pubitemid 28218417)
71. Kleiber M. (1947). Body size and metabolic rate. Physiol Rev27:511-541.
72. Krieter PA, Trapani AJ. (1989). Metabolism of atrial natriuretic peptide. Extraction by organs in the rat. Drug Metab Dispos 17:14-19. (Pubitemid 19058157)
73. Kurihara A, Naganuma H, Hisaoka M, Tokiwa H, Kawahara Y. (1992). Prediction of human pharmacokinetics of panipenembetamipron, a new carbapenem, from animal data. Antimicrob Agents Chemother 36:1810-1816.
74. Kuwabara T, Kato Y, Kobayashi S, Suzuki H, Sugiyama Y. (1994). Nonlinear pharmacokinetics of a recombinant human granulocyte colony-stimulating factor derivative (nartograstim): species differences among rats, monkeys and humans. J Pharmacol Exp Ther 271:1535-1543. (Pubitemid 24382668)
75. Lai Y, Sampson KE, Balogh LM, Brayman TG, Cox SR, Adams WJ, Kumar V, Stevens JC. (2010). Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). J Pharmacol Exp Ther 334:936-944.
76. Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P. (1997). Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 86:584-590. (Pubitemid 27203406)
77. Lave T, Levet-Trafit B, Schmitt-Hoffmann AH, Morgenroth B, Richter W, Chou RC. (1995). Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. J Pharm Sci 84:1285-1290.
78. Lave T, Saner A, Coassolo P, Brandt R, Schmitt-Hoffmann AH, Chou RC. (1996). Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. J Pharm Pharmacol 48:573-577. (Pubitemid 26254692)
79. Lepist EI, Jusko WJ. (2004). Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis. J Vet Pharmacol Ther 27:211-218. (Pubitemid 39141606)
80. Levin AA. (1999). A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1489:69-84.
81. Levin AA, Yu RZ, Geary RS. (2001). Basic principles of the pharmacokinetics of antisense oligonucleotide drugs, CRC Press.
82. Lin JH. (2009). Pharmacokinetics of Biotech Drugs: Peptides, Proteins and Monoclonal Antibodies. Curr Drug Metab 10:661-691.
83. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB. (1999). Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371-378. (Pubitemid 29113511)
84. Ling J, Zhou H, Jiao Q, Davis HM. (2009). Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 49:1382-1402.
85. Lobo ED, Hansen RJ, Balthasar JP. (2004). Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645-2668. (Pubitemid 39506617)
86. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B. (2006). Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 1:1211-1215.
87. Mahmood I. (1998). Interspecies scaling of renally secreted drugs. Life Sci 63:2365-2371. (Pubitemid 28557275)
88. Mahmood I. (2004). Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci 93:177-185. (Pubitemid 38081825)
89. Mahmood I.(2005) Prediction of clearance using monkey liver blood flow, Rockville, Pine House Publishers
90. Mahmood I. (2009). Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept. Drug Metabol Drug Interact 24:57-81.
91. Mahmood I. (2009). Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci 98:3850-3861.
92. Mahmood I, Balian JD. (1996). Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887-895. (Pubitemid 26343083)
93. Marleau S, Ong H, De Lean A, du Souich P. (1989). Disposition and dynamics of atrial natriuretic factor in conscious rabbits. J Pharmacol Exp Ther 251:328-333. (Pubitemid 19261983)
94. Martin U, K̂hler J, Sponer G, Strein K. (1992). Pharmacokinetics of the novel recombinant plasminogen activator BM 06.022 in rats, dogs, and non-human primates. Fibrinolysis 6:39-43.
95. Martin U, von Mollendorff E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. (1991). Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. Thromb Haemost 66:569-574.
96. Matsushita H, Suzuki H, Sugiyama Y, Sawada Y, Iga T, Hanano M, Kawaguchi Y. (1990). Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals. J Pharmacobio-dyn 13:602-611. (Pubitemid 20386462)
97. McCarthy K, Stewart P, Sigman J, Read M, Keith JC Jr, Brinkhous KM, Nichols TC, Schaub RG. (2002). Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb Haemost 87:824-830. (Pubitemid 34516609)
98. Mellett LB. (1969). Comparative drug metabolism. Prog Drug Res 13:136-169.
99. Monzani MV, Coltro G, Jiritano L, Sala A. (1995). Pharmacokinetic profile of ITF 296 in rats and dogs. J Cardiovasc Pharmacol 26 Suppl 4:S67-S71. (Pubitemid 26069771)
100. Monzani MV, Coltro G, Sala A, Sardina M. (1999). Pharmacokinetics of ITF 296 (Sinitrodil) a novel organic nitrate, in healthy volunteers. Eur J Pharm Sci 7:179-184. (Pubitemid 29015733)
101. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. (1991). Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 8:1351-1359.
102. Mordenti J, Osaka G, Garcia K, Thomsen K, Licko V, Meng G. (1996). Pharmacokinetics and interspecies scaling of recombinant human factor VIII. Toxicol Appl Pharmacol 136:75-78. (Pubitemid 26049711)
103. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM. (2009). Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol 27:3346-3353.
104. Mroszczak EJ, Lee FW, Combs D, Sarnquist FH, Huang BL, Wu AT, Tokes LG, Maddox ML, Cho DK. (1987). Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. Drug Metab Dispos 15:618-626. (Pubitemid 18004616)
105. Mullamitha SA, Ton NC, Parker GJ, Jackson A, Julyan PJ, Roberts C, Buonaccorsi GA, Watson Y, Davies K, Cheung S, Hope L, Valle JW, Radford JA, Lawrance J, Saunders MP, Munteanu MC, Nakada MT, Nemeth JA, Davis HM, Jiao Q, Prabhakar U, Lang Z, Corringham RE, Beckman RA, Jayson GC. (2007). Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 13:2128-2135. (Pubitemid 46649882)
106. Murthy SS, Nelson WL, Shen DD, Power JM, Cahill CM, McLean AJ. (1991). Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects. Drug Metab Dispos 19:1093-1100.
107. Nagilla R, Ward KW. (2004). A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci 93:2522-2534. (Pubitemid 39319435)
108. Nakagawa K, Koyama M, Matsui H, Ikeda C, Yano K, Nakatsuru N, Yoshinaga K, Noguchi T. (1984). Pharmacokinetics of cefpiramide (SM-1652) in humans. Antimicrob Agents Chemother 25:221-225.
109. Nakamura S, Kurobe N, Kashimoto S, Ohue T, Takase Y, Shimizu M. (1983). Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. Antimicrob Agents Chemother 24:54-60. (Pubitemid 13076179)
110. Neville K, Parise RA, Thompson P, Aleksic A, Egorin MJ, Balis FM, McGuffey L, McCully C, Berg SL, Blaney SM. (2004). Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res 10:2525-2529. (Pubitemid 38445714)
111. Nouws JF, Mevius DJ, Vree TB, Baars AM, Laurensen J. (1988). Pharmacokinetics, renal clearance and metabolism of ciprofloxacin following intravenous and oral administration to calves and pigs. Vet Q 10:156-163.
112. Nowak G. (1991). Pharmacokinetics of hirudin. Semin Thromb Hemost 17:145-149.
113. Obach RS, Lombardo F, Waters NJ. (2008). Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36:1385-1405. (Pubitemid 351929323)
114. Ohdo S, Arata N, Furukubo T, Yukawa E, Higuchi S, Nakano S, Ogawa N. (1998). Chronopharmacology of granulocyte colony-stimulating factor in mice. J Pharmacol Exp Ther 285:242-246. (Pubitemid 28207592)
115. Oikawa K, Kamimura H, Watanabe T, Miyamoto I, Higuchi S. (2001). Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys. Thromb Res 101:493-500. (Pubitemid 32367926)
116. Oikawa K, Watanabe T, Miyamoto I, Higuchi S. (2000). Determination, pharmacokinetics and protein binding of a novel tissue-type plasminogen activator, pamiteplase in human plasma. Xenobiotica 30:993-1003.
117. Olsen KM, Martin SJ. (2002). Pharmacokinetics and clinical use of drotrecogin alfa (activated) in patients with severe sepsis. Pharmacotherapy 22:196S-205S. (Pubitemid 35429942)
118. Oostendorp RL, Buckle T, Beijnen JH, van Tellingen O, Schellens JH. (2009). The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 27:31-40.
119. Palframan R, Airey M, Moore A, Vugler A, Nesbitt A. (2009). Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 348:36-41.
120. Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R, Lloyd P. (2004). Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44:158-162. (Pubitemid 38114314)
121. Prandota J, Pruitt AW. (1991). Pharmacokinetic, biliary excretion, and metabolic studies of 14C-furosemide in the rat. Xenobiotica 21:725-736.
122. Puchalski T, Prabhakar U, Jiao Q, Berns B, Davis HM. (2010). Pharmacokinetic and pharmacodynamic modeling of an antiinterleukin- 6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 16:1652-1661.
123. Radwanski E, Chakraborty A, Van Wart S, Huhn RD, Cutler DL, Affrime MB, Jusko WJ. (1998). Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharm Res 15:1895-1901. (Pubitemid 29034840)
124. Rane A, Hogstedt S, Lindberg B, Regardh CG, Jorulf H. (1984). Comparison of different clearance estimates for metoprolol in the rhesus monkey. J Pharmacol Exp Ther 228:774-778. (Pubitemid 14156687)
125. Richter W F, Gallati H, Schiller C D. (1999). Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab Dispos 27:21-25. (Pubitemid 29060995)
126. Richter WF, Heizmann P, Meyer J, Starke V, Lave T. (1998). Animal pharmacokinetics and interspecies scaling of Ro 25-6833 and related (lactamylvinyl)cephalosporins. J Pharm Sci 87:496-500. (Pubitemid 28175812)
127. Ritschel WA, Vachharajani NN, Johnson RD, Hussain AS. (1991). Interspecies scaling of the pharmacokinetic parameters of coumarin among six different mammalian species. Methods Find Exp Clin Pharmacol 13:697-702.
128. Robbie G, Chiou WL. (1998). Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling. Pharm Res 15:1630-1636. (Pubitemid 28465752)
129. Rojas JR, Taylor RP, Cunningham MR, Rutkoski TJ, Vennarini J, Jang H, Graham MA, Geboes K, Rousselle SD, Wagner CL. (2005). Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 313:578-585. (Pubitemid 40604157)
130. Sacher GA. (2008) Relation of Lifespan to Brain Weight and Body Weight in Mammals, John Wiley & Sons, Ltd
131. Sangalli L, Bortolotti A, Jiritano L, Bonati M. (1988). Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. Drug Metab Dispos 16:749-753.
132. Sardina M, Love R, Mizrahi J, Monzani V, Bianchini C. (1995). Safety and pharmacologic activity of a new nitrate ester, ITF 296, after intravenous administration in healthy volunteers. J Cardiovasc Pharmacol 26 Suppl 4:S72-S79. (Pubitemid 26069772)
133. Sewell KL, Geary RS, Baker BF, Glover JM, Mant TG, Yu RZ, Tami JA, Dorr FA. (2002). Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 303:1334-1343. (Pubitemid 35424421)
134. Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. (1999). A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 52:1072-1074. (Pubitemid 29161624)
135. Siefert HM, Maruhn D, Scholl H. (1986). Pharmacokinetics of ciprofloxacin. 2nd communication: distribution to and elimination from tissues and organs following single or repeated administration of [14C]ciprofloxacin in albino rats. Arzneimittelforschung 36:1503-1510. (Pubitemid 16023812)
136. Srinivas NR, Shyu WC, Weiner RS, Warner G, Comereski C, Tay LK, Greene DS, Barbhaiya RH. (1997). Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats. Pharm Res 14:911-916. (Pubitemid 27326987)
137. Srinivas NR, Weiner RS, Shyu WC, Calore JD, Tritschler D, Tay LK, Lee JS, Greene DS, Barbhaiya RH. (1996). A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in mice. J Pharm Sci 85:296-298. (Pubitemid 26082474)
138. Srinivas NR, Weiner RS, Warner G, Shyu WC, Davidson T, Fadrowski CG, Tay LK, Lee JS, Greene DS, Barbhaiya RH. (1996). Pharmacokinetics and pharmacodynamics of CTLA4lg (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses. J Pharm Sci 85:1-4.
139. Stokol T, Trepanier L, Parry BW, Finnin BC. (1997). Pharmacokinetics of von Willebrand factor and factor VIII in canine von Willebrand disease and haemophilia A. Res Vet Sci 63:23-27.
140. Tanaka E, Ishikawa A, Horie T. (1999). In vivo and in vitro trimethadione oxidation activity of the liver from various animal species including mouse, hamster, rat, rabbit, dog, monkey and human. Hum Exp Toxicol 18:12-16. (Pubitemid 29054467)
141. Tang L, Persky AM, Hochhaus G, Meibohm B. (2004). Pharmacokinetic aspects of biotechnology products. J Pharm Sci 93:2184-2204. (Pubitemid 39129617)
142. Tanswell P, Modi N, Combs D, Danays T. (2002). Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 41:1229-1245. (Pubitemid 36026764)
143. Tranum BL, Stephens RL, Lehane DE, Hoogstraten B, Lane M, Haut A. (1975). Adriamycin (NSC-123127) plus 5-fluorouracil (NSC- 19893): a phase I study. Cancer Chemother Rep 59:1163-1165.
144. Tsunekawa Y, Hasegawa T, Nadai M, Takagi K, Nabeshima T. (1992). Interspecies differences and scaling for the pharmacokinetics of xanthine derivatives. J Pharm Pharmacol 44:594-599.
145. Ueda CT, Ballard B, Rowland M. (1977). Concentration-time effects of quinidine disposition kinetics in rhesus monkeys. J Pharmacol Exp Ther 200:459-468. (Pubitemid 8089834)
146. Ujhelyi MR, Robert S. (1995). Pharmacokinetic aspects of digoxinspecific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet 28:483-493.
147. Valverde CR, Mama KR, Kollias-Baker C, Steffey EP, Baggot JD. (2000). Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane- anesthetized rhesus monkeys (Macaca mulatta). Am J Vet Res 61:931-934. (Pubitemid 30639912)
148. Wang W, Prueksaritanont T. (2010). Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos 31:253-263.
149. Ward KW, Smith BR. (2004). A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 32:603-611. (Pubitemid 38668152)
150. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK. (2003). Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with
151. White G, Shapiro A, Ragni M, Garzone P, Goodfellow J, Tubridy K, Courter S. (1998). Clinical evaluation of recombinant factor IX. Semin Hematol 35:33-38. (Pubitemid 28177999)
152. Woo S, Jusko WJ. (2007). Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos 35:1672-1678. (Pubitemid 47296063)
153. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH. (1986). Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci 38: 1827-1833. (Pubitemid 16068742)
154. Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS. (2007). Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 35:460-468. (Pubitemid 46333910)